CAMBIUM BIO LIMITED — AGM Information 2014

Oct 27, 2014

2014 AGM Presentation

Sydney 28 October 2014

“Improving quality of life through innovative cellular therapies”

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Important Notice
----- End of picture text -----

Forward-Looking Statements

This Presentation contains certain statements which constitute forward-looking statements or information ("forwardlooking statements”). These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the general economic and industry conditions in Australia and globally and the operations of the Company. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the Company believes the expectations and assumptions reflected in the forward-looking statements are reasonable, as of the date hereof, undue reliance should not be placed on the forward-looking statements as the Company can give no assurances that they will prove correct and because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risks associated with biotechnology companies, regenerative medicine and associated life science companies; delays or changes in plans; specific risks associated with the regulatory approvals for or applying to the Company’s products; commercialisation of the Company’s products and research and development of the Company’s products; ability to execute production sharing contracts, ability to meet work commitments, ability to meet the capital expenditures; risks associated with stock market volatility and the ability of the Company to continue as a going concern. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by securities laws.

No offer to sell, issue or recommend securities

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction. Neither this presentation nor anything in it will form any part of any contract for the acquisition of securities.

Page 2

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Agenda
----- End of picture text -----

1. Significant Achievements to date

2. FY14 Highlights

3. Financial Results

4. Product Pipeline Update and Value

5. FY15 Strategic Imperatives

6. Product Overview

– FY14 Achievements

– FY15 Milestones

1. IP Update

Title of Document Can be Changed on Master Page

Page 3

Significant Achievements to date

==> picture [48 x 48] intentionally omitted <==

Successful translation of 4 regenerative medicine technology platforms into products for musculoskeletal and oncology applications for humans and animals Pioneered autologous (‘08) and allogeneic (’11) adipose stem cell therapy for animals in Australia

==> picture [48 x 48] intentionally omitted <==

World’s first placebo controlled RCT for autologous adipose stem cell therapy for human knee OA

==> picture [48 x 48] intentionally omitted <==

Largest registry following patients treated with adipose stem cells for human musculoskeletal conditions

==> picture [642 x 105] intentionally omitted <==

----- Start of picture text -----

USDA green light for first autologous canine cancer vaccine (Kvax)
On track for CryoShot Canine to be one of the first stem cell products approved by
FDA
----- End of picture text -----

Title of Document Can be Changed on Master Page

Page 4

FY14 Highlights

==> picture [644 x 335] intentionally omitted <==

----- Start of picture text -----

Completed IPO
Opened INAD with FDA for CryoShot Canine
Entered into manufacturing agreement with Lonza for CryoShot Canine for FDA
trial and commercial product
>500 patients and 1200 joints now treated with HiQCell
Received green light from USDA for Kvax commercial offering in US
Secured exclusive rights for human applications of cancer vaccine technology
Manufactured cells for first-in-man trial of allogeneic stem cells for knee OA
----- End of picture text -----

Title of Document Can be Changed on Master Page

Page 5

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Financial Results
----- End of picture text -----

S’000’s	2014	2013	FY 2014 – Key Financial Highlights • Revenue up 18% to $2.1 million • Targeted R&D expenditure up 39% to $5.8 million • R&D tax incentive increased 60% to $3.7 million • Successful IPO supported by additional funding Q1 FY15 totalling $16.5 million • Cash at 30 June 2014 $2.5 million
Revenue	2,095	1,770
Cost of Sales	(622)	(581)
Gross Profit	1,473	1,189
Other Income (inc R&D incentive)	3,868	2,628
R&D expenses	(5,759)	(4,134)
Selling expenses	(2,253)	(1,784)
Corporate expenses	(3,875)	(2,297)
Occupancy expenses	(628)	(468)
Finance Expenses	(349)	(329)
Loss for year	(7,523)	(5,195)

Title of Document Can be Changed on Master Page

Page 6

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Operating Cash Burn
----- End of picture text -----

S’000’s	Q4 FY 15 Target	Q1 FY 15	June 2014	June 2013
Cash on Hand (period end)	3,500+	9,601	2,508	411
R&D Tax Incentive		3,731	2,327	1,679
Normalised Quarterly Operating Cash Burn	1,700	2,558	8,566	6,297

• Accelerated R&D expenditure normalised Q2/Q3 FY 15

• R&D tax incentive of $2.6+ million received Q1 FY 16 (not included in above)

• Singapore profitable Q4 FY 15

• End FY 2015 ‘Cash Burn’ Quarterly target $1.7 million (Qtr 1 FY 15 $2.6 million)

Page 7

==> picture [721 x 541] intentionally omitted <==

----- Start of picture text -----

Product Pipeline Update
PRODUCT& INDICATION& PRECLINICAL& PHASE&1& PHASE&2& PHASE&3& MARKETED&
Osteoarthri/s' Exempt'Biological'
HiQCell''
Neuropathic'Pain' Exempt'Biological'
Progenza' Osteoarthri/s'
Inflammatory'Skin'
Secre/ons'Cream' NICNAS'
Condi/ons'
Cancer'Vaccine' Oncology' Exempt'Biological'
PRODUCT' INDICATION' PRECLINICAL' CLINICAL' MARKETED'
CryoShot'Canine'' Osteoarthri/s' Trials'(AUS/CAN);'INAD'open'(US)'
CryoShot'Equine' Osteoarthri/s' Field'trials'(AUS)'
AUS/US'available'for'
Kvax' Oncology'
commercialisa/on'
Autologous' Allogeneic' Xenogeneic''' Autologous' 'Exempt'biological'under''
Adipose'MSCs' Adipose'MSCs' Adipose'MSCs' Tumour'Cells' '''Australian'regula/ons''
Autologous&cells& –'means'a'pa/ent’s'own'cells' Allogeneic&cells& –'means'cells'from'a'donor'of'the' Xenogeneic&cells& –'means'cells'from'a'donor'of'a'
same'species'' different'species'
DRAFCan be Changed on Master Page Page 8
HUMAN&
VETERINARY'
----- End of picture text -----

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Relative Value of Products
----- End of picture text -----

==> picture [597 x 270] intentionally omitted <==

----- Start of picture text -----

Human
HiQCell HiQCell cancer
Australia Internation vaccine
4% al 3%
3% HiQCell
Internatio
Human HiQCell nal
cancer Kvax Australia 9%
vaccine 13% 11%
14%
Kvax
6%
CryoShot
13%
CryoShot
Progenza
Progenza 33%
(PRG)
(PRG)
31%
60%
----- End of picture text -----

Net Present Value

rNPV per share

• Analysis based on Edison Investment Research Report 1 October 2014

• Valuation $0.71c per share or $148m

• RGS is a research client of Edison

Page 9

FY15 Strategic Imperatives

==> picture [642 x 330] intentionally omitted <==

----- Start of picture text -----

Drive HiQCell business to profitability and seek partnering opportunities
Seek global sales and marketing partner for Kvax
Seek global sales and marketing partner for CryoShot Canine
Commence human cancer vaccine safety trial in Q2’15
Commence PRG human safety trial in Q2’15
Seek Japanese partner for PRG
----- End of picture text -----

Page 10

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

HiQCell – cell therapy for OA
----- End of picture text -----

FY14 Achievements

• 197 procedures – introduced cryostorage option

• Over 1200 joints and 500 patients now treated

• Launched HiQCell in Melbourne with Sports Med Biologic

• Established processing facility at new East Sydney Day Hospital

• Introduced 4 new treating specialists

• Development and implementation of outbound direct patient marketing and follow-on enquiry handling / recruitment

• Preparation for launch in Singapore in November ’14

• Release of latest Joint Registry data

• Publication of HiQCell case study for neuropathic pain patients

==> picture [229 x 186] intentionally omitted <==

==> picture [229 x 196] intentionally omitted <==

Page 11

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

HiQCell – cell therapy for OA
----- End of picture text -----

FY15 Milestones

• Further marketing initiatives to referrers, patients and other stakeholders

• Publication of safety and efficacy evidence – OSCARS, Registry, case studies

• Commitment to further clinical studies – important for TMP engagement and further efficacy evidence

• Leverage clinical data and case studies to enhance media understanding

• 3[rd] party payer / reimbursement exploration – evidence data and pathway forward

• Commence procedures in Singapore

==> picture [288 x 97] intentionally omitted <==

==> picture [288 x 72] intentionally omitted <==

==> picture [288 x 148] intentionally omitted <==

• Explore partnering/licensing options

Page 12

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Kvax – canine cancer vaccine
----- End of picture text -----

FY14 Achievements

• Commercially available in Australia September 2014

• USDA sign off for commercialisation in US

• Establish US manufacturing capability with Hennessey Research

• Publication of paper in Cancer Immunology

• Commenced marketing trial with Dr Phil Bergman of VCA, largest US vet services group

• Tech transfer from Kolling to RGS and RGS to Hennessey Research

==> picture [280 x 159] intentionally omitted <==

==> picture [159 x 128] intentionally omitted <==

==> picture [160 x 128] intentionally omitted <==

Page 13

DRAFCan be Changed on Master Page

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Kvax – canine cancer vaccine
----- End of picture text -----

FY15 Milestones

• Increase marketing activities for Kvax in Australia

• Seek global sales and marketing partner

==> picture [287 x 164] intentionally omitted <==

• Confirm market access to UK/EU and Japanese markets

• • Commence further marketing trials

DRAFCan be Changed on Master Page

==> picture [160 x 128] intentionally omitted <==

Page 14

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Human Cancer Vaccine
----- End of picture text -----

FY14 Achievements

• Secured exclusive rights to human applications

FY15 Milestones

• First-in-man trial expected to commence in first half 2015 with lead investigators from RNSH

==> picture [248 x 137] intentionally omitted <==

==> picture [248 x 120] intentionally omitted <==

• Confirm accelerated regulatory pathways as autologous therapy

DRAFCan be Changed on Master Page

Page 15

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

CryoShot Canine
----- End of picture text -----

FY14 Achievements

• INAD opened with FDA for CryoShot Canine FDA registration trial

• Manufacturing agreement with Lonza for GMP product development and trial product

• Further data collected from field trials in Australia

• Commenced RCT in Australia to de-risk FDA trial

FY15 Milestones

• Readout from local RCT

• Sign off on trial design, product characterisation and manufacture for FDA trial scheduled for Q4 2015

• Seek partner for sales and marketing

DRAFCan be Changed on Master Page

Page 16

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Progenza (PRG) – targeting Japan
----- End of picture text -----

FY14 Achievements

• Development of manufacturing methods for allogeneic adipose derived stem cell product for human OA – using CryoShot platform

• Established production capability at Cryosite for first-in-man trial

• Ethics approved procurement of donor adipose tissue

• Manufacture of seed bank

• Confirmation that PRG would be eligible for conditional approval product approval under new Japanese regulations

• Detailed analysis of Japanese market opportunity

DRAFCan be Changed on Master Page

Page 17

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Progenza (PRG) – targeting Japan
----- End of picture text -----

FY15 Milestones

• Completion of pre-clinical study

• Ethics approval for first-in man trial

• Commencement of first-in-man trial

• Seek Japanese partner for development and commercialisation in Japan

==> picture [314 x 228] intentionally omitted <==

DRAFCan be Changed on Master Page

Page 18

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Patent Portfolio Update
----- End of picture text -----

• 11 patent families

• 2 new families since IPO

• Cancer vaccine licensed from Kolling Institute

– Biomarkers for monitoring efficacy of cell therapies

• 7 applications have reached Accepted status in Australia

• Expect these to be granted before July 2015

Title of Document Can be Changed on Page 20 Master Page

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Patent Portfolio
----- End of picture text -----

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Patent Portfolio
----- End of picture text -----

Title of Document Can be Changed on Page 21

Master Page

==> picture [685 x 71] intentionally omitted <==

----- Start of picture text -----

Resolution of Patent Oppositions
----- End of picture text -----

• Opposition to an application (AU2009201915) from Family 1 was lodged by Norwood Immunology Ltd

• Norwood and its sister company Magellan Stem Cells opposed two related applications from Family 1A and three other Regeneus applications

• Reached an agreement with Norwood/Magellan Stem Cells

• All oppositions are in the process of being withdrawn

FY15 Strategic Imperatives

==> picture [48 x 48] intentionally omitted <==

==> picture [48 x 48] intentionally omitted <==

Grow HiQCell procedure rates and seek partnering opportunities Seek global sales and marketing partner for canine cancer vaccine, Kvax Seek global sales and marketing partner for CryoShot Canine Commence human cancer vaccine safety trial in Q2’15 Commence PRG human safety trial in Q2’15 Seek Japanese partner for PRG

Page 23

Thank you and questions